It has been shown that both CD55 and CD59 and other complement regulators are capable of attenuating T-cell responses and proliferation [24]–[29], which might explain the increased expression of CD55 and CD59 on leukocytes and their subsets according to disease severity and a possible involvement in HUS and HUS/N. This evidence concerns the gene CD59 and hemolytic-uremic syndrome.